Legacy-Xspire Holdings

Legacy-Xspire Holdings is a specialty pharmaceutical company focused on the development and commercialization of prescription products in the United States. Formed through the merger of Legacy Pharmaceuticals and Xspire Pharma, the company maintains a strategic focus on therapeutic areas including respiratory health, allergy, and dermatology. Its commercial portfolio is anchored by Karbinal ER, an extended-release antihistamine, and Ryvent, a high-potency antihistamine tablet. The organization leverages a specialized sales force to engage with healthcare providers and ensure patient access to its therapeutic offerings. Legacy-Xspire aims to provide clinically effective and cost-efficient solutions for common allergic and respiratory conditions.